Kronos Bio Revenue and Competitors
Estimated Revenue & Valuation
- Kronos Bio's estimated annual revenue is currently $19.7M per year.
- Kronos Bio's estimated revenue per employee is $149,129
- Kronos Bio's total funding is $278M.
- Kronos Bio's current valuation is $601.8M. (January 2022)
Employee Data
- Kronos Bio has 132 Employees.
- Kronos Bio grew their employee count by 8% last year.
Kronos Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Sr. VP, Biology | Reveal Email/Phone |
3 | Executive Director Business Development | Reveal Email/Phone |
4 | SVP, Drug Discovery | Reveal Email/Phone |
5 | VP, Product Development and Manufacturing | Reveal Email/Phone |
6 | VP, Assistant General Counsel | Reveal Email/Phone |
7 | Senior Director, Corporate Administration | Reveal Email/Phone |
8 | Director Computational Biology | Reveal Email/Phone |
9 | Director | Reveal Email/Phone |
10 | Director, Computational Chemistry | Reveal Email/Phone |
Kronos Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Kronos Bio?
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.
keywords:N/A
$278M
Total Funding
132
Number of Employees
$19.7M
Revenue (est)
8%
Employee Growth %
$601.8M
Valuation
N/A
Accelerator
Kronos Bio News
Item 5.02 Other Events. On April 20, 2022 , the Compensation Committee of the Board of Directors of. Kronos Bio, Inc. (the "Company")...
This table compares Clovis Oncology and Kronos Bio's revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net Income...
Kronos Bio continues to enroll patients in Phase 1/2 clinical trial, with additional data anticipated in Q4 2022.
Kronos Bio announced private financing of about $155 million of convertible notes with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments Kronos Bio – a private clinical-stage biopharmaceutical company dedicated to ...
Other Companies in San Mateo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.9M | 133 | -9% | N/A |
#2 | $19.3M | 133 | N/A | N/A |
#3 | $43.6M | 134 | -9% | N/A |
#4 | $26.9M | 134 | 4% | N/A |
#5 | $21.6M | 135 | 10% | N/A |